In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment.
Détails
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_DEEE58BD8725
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment.
Périodique
The Journal of Infectious Diseases
ISSN
0022-1899
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
199
Numéro
4
Pages
576-579
Langue
anglais
Résumé
The presence of intralesional natural regulatory T cells, characterized by the expression of Foxp3 mRNA, was analyzed in patients with localized leishmaniasis due to Leishmania guyanensis infection that was unresponsive to treatment with pentamidine isethionate. Foxp3 mRNA levels were associated with unresponsiveness to treatment among patients with a lesion duration of 1 month, but this association was not observed among patients with a lesion duration of <1 month. In conclusion, high intralesional expression of Foxp3 might be an indicator of poor response to treatment, depending on the duration of lesions.
Mots-clé
Adolescent, Adult, Animals, Antiprotozoal Agents/therapeutic use, Female, Forkhead Transcription Factors/genetics, Forkhead Transcription Factors/metabolism, Gene Expression Regulation, Humans, Interleukin-10/genetics, Interleukin-10/metabolism, Leishmania guyanensis/drug effects, Leishmaniasis, Cutaneous/drug therapy, Leishmaniasis, Cutaneous/immunology, Male, Middle Aged, Pentamidine/therapeutic use, RNA, Messenger/genetics, RNA, Messenger/metabolism, T-Lymphocytes, Regulatory/immunology, T-Lymphocytes, Regulatory/metabolism, Treatment Failure
Pubmed
Web of science
Open Access
Oui
Création de la notice
17/08/2009 12:13
Dernière modification de la notice
14/02/2022 7:57
Données d'usage
